Literature DB >> 11019787

Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.

A Shuper1, B Stark, L Kornreich, I J Cohen, S Aviner, A Steinmetz, J Stein, Y Goshen, I Yaniv.   

Abstract

Methotrexate can influence the central nervous system through several metabolic toxic pathways. These effects can be categorized as immediate, acute to subacute, or chronic neurologic syndromes. The acute to subacute syndrome occurs frequently in acute lymphoblastic leukemia treatment protocols, generally manifesting with focal neurologic signs and changes seen on magnetic resonance imaging and single photon emission computed tomography. While in some patients the neurotoxicity is transient and benign and allows for continuation of chemotherapy, in others it can be quite severe and debilitating, leading to permanent neurologic deficits. The need to modify the treatment protocols when neurotoxicity appears is not fully established. It is also unknown whether the use of sufficient amounts of leucovorin can overcome the toxic effects of the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019787     DOI: 10.1177/088307380001500902

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  15 in total

1.  Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features.

Authors:  France Ziereisen; Bernard Dan; Nadira Azzi; Alina Ferster; Nash Damry; Catherine Christophe
Journal:  Pediatr Radiol       Date:  2005-12-21

Review 2.  [White matter alterations after chemotherapy and radiation].

Authors:  A Simgen
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

3.  Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children.

Authors:  Michael J Fisher; Zarir P Khademian; Erin M Simon; Robert A Zimmerman; Larissa T Bilaniuk
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

Review 4.  Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.

Authors:  Sharon M Castellino; Nicole J Ullrich; Megan J Whelen; Beverly J Lange
Journal:  J Natl Cancer Inst       Date:  2014-07-30       Impact factor: 13.506

5.  Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments.

Authors:  Alessandra Erbetta; Andrea Salmaggi; Angelo Sghirlanzoni; Antonio Silvani; Paolo Potepan; Andrea Botturi; Elisa Ciceri; Maria Grazia Bruzzone
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

Review 6.  Neuropsychological sequelae of non-central nervous system cancer and cancer therapy.

Authors:  Jeffrey S Wefel; Mariana E Witgert; Christina A Meyers
Journal:  Neuropsychol Rev       Date:  2008-04-16       Impact factor: 7.444

7.  Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings.

Authors:  Fulvia Brugnoletti; E Brannon Morris; Fred H Laningham; Zoltán Patay; Jennifer L Pauley; Ching-Hon Pui; Sima Jeha; Hiroto Inaba
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

8.  Decreased postural control in adult survivors of childhood cancer treated with chemotherapy.

Authors:  Einar-Jón Einarsson; Mitesh Patel; Hannes Petersen; Thomas Wiebe; Per-Anders Fransson; Måns Magnusson; Christian Moëll
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

9.  Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.

Authors:  Hauke Rühs; Achim Becker; Anne Drescher; John C Panetta; Ching-Hon Pui; Mary V Relling; Ulrich Jaehde
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.